Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided statements appropriately capture the FDA label’s pregnancy contraindication (embryo-fetal toxicity), pregnancy exclusion/testing prior to initiation, effective contraception during treatment and for one month after stopping, and discontinuation as soon as possible when pregnancy is detected. No direct contradictions to the supplied label content were identified.
Category Scores
Accurate Statements
OPSUMIT is contraindicated during pregnancy due to embryo-fetal toxicity.
Supported by BOX and Contraindications (4.1); Warnings/Precautions (5.1); Use in Specific Populations (8.1).
Exclude pregnancy prior to initiation of treatment with OPSUMIT.
Supported by BOX and Dosage and Administration (2.2) and Use in Specific Populations (8.3).
Use effective contraception during treatment and for one month after stopping OPSUMIT.
Supported by BOX and Warnings/Precautions (5.1) and Use in Specific Populations (8.3).
When pregnancy is detected, discontinue OPSUMIT as soon as possible.
Supported by BOX and Warnings/Precautions (5.1).
Unsupported Statements
Opusmit’s active ingredient is macitentan.
The supplied label excerpts for pregnancy do not state the active ingredient.
Generic versions of Opsumit (macitentan) are possible once legal exclusivity and regulatory requirements are satisfied.
Not addressed in the supplied FDA pregnancy-related label excerpts.
The biosimilar pathway does not apply to Opsumit; a generic version would follow a standard small-molecule generic approval route.
Not addressed in the supplied FDA pregnancy-related label excerpts.
When switching to a generic, patients should confirm the strength (dose), the active ingredient (macitentan), and the manufacturer.
Not addressed in the supplied FDA pregnancy-related label excerpts.
Main practical risks of switching include dosing differences and lack of interchangeability if formulations are not truly equivalent.
Not addressed in the supplied FDA pregnancy-related label excerpts.
Clinicians typically advise more close monitoring when switching pulmonary arterial hypertension medicines, especially if symptoms worsen or side effects change.
Not addressed in the supplied FDA pregnancy-related label excerpts.
Contradictions
Important Omissions
The label’s instruction to obtain a pregnancy test prior to initiation is stated in the BOX/W&P/Dosage section but the AI content provided here is evaluated only against the pregnancy workflow items included; if the AI omitted 'obtain a pregnancy test prior to initiation' wording, this would be a moderate omission (however the supplied pregnancy workflow guidance in the AI claim includes excluding pregnancy prior to initiation, which is closely aligned).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Pregnancy contraindication and associated required precautions (exclude pregnancy, contraception, discontinue promptly) match the supplied label content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several non-pregnancy-related statements (e.g., generics/biosimilars pathways, switching guidance) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to the pregnancy-specific label text supplied (contraindication in pregnancy, pregnancy testing/exclusion, contraception timing, and discontinuation upon pregnancy detection) or provide additional label excerpts covering generics/switching topics.